[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=52dd314095a3b0afca981b67c88f06cea0ae4b067e697ab736e5239e95a69271",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767794404,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
      "id": 138027263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=52dd314095a3b0afca981b67c88f06cea0ae4b067e697ab736e5239e95a69271"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies",
    "summary": "Check out the companies making headlines yesterday:",
    "url": "https://finnhub.io/api/news?id=c28d15451635bbbbdb45eb455b25fe5d38f01ff141f111256098e1d5c0b32300",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767790838,
      "headline": "Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies",
      "id": 138027117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Check out the companies making headlines yesterday:",
      "url": "https://finnhub.io/api/news?id=c28d15451635bbbbdb45eb455b25fe5d38f01ff141f111256098e1d5c0b32300"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Says These 2 Healthcare Stocks Are Top Ideas for 1Q26",
    "summary": "As 2026 gets rolling, it’s only natural to want to find the best stocks to boost the portfolio in the New Year. The analysts at Bank of America know this, and they are busy picking out shares that are poised to bring rapid gains, with returns coming in during this new first quarter. While it may sound counterintuitive – most advisors will tell you to play a long game – it doesn’t negate a long-term strategy; rather, a solid short-term game plan will provide a solid complement to it, and a more b",
    "url": "https://finnhub.io/api/news?id=e78a18bfea1c9bf93bc7b1586bff47e7ef7b1f90121b661c94c8e5f2fe52fbc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767783601,
      "headline": "Bank of America Says These 2 Healthcare Stocks Are Top Ideas for 1Q26",
      "id": 138025830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "As 2026 gets rolling, it’s only natural to want to find the best stocks to boost the portfolio in the New Year. The analysts at Bank of America know this, and they are busy picking out shares that are poised to bring rapid gains, with returns coming in during this new first quarter. While it may sound counterintuitive – most advisors will tell you to play a long game – it doesn’t negate a long-term strategy; rather, a solid short-term game plan will provide a solid complement to it, and a more b",
      "url": "https://finnhub.io/api/news?id=e78a18bfea1c9bf93bc7b1586bff47e7ef7b1f90121b661c94c8e5f2fe52fbc8"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's top 10 things to watch in the stock market Wednesday",
    "summary": "The stock market was little changed this morning after the S&P 500 hit records highs Tuesday.",
    "url": "https://finnhub.io/api/news?id=a57b975de029806c09eb01c4b7ec39385868263fc9dfb7e3d6ee1aa602c63b5b",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767777423,
      "headline": "Jim Cramer's top 10 things to watch in the stock market Wednesday",
      "id": 138027947,
      "image": "https://image.cnbcfm.com/api/v1/image/107200469-1677528554271-NUP_200782_00155.jpg?v=1721682202&w=1920&h=1080",
      "related": "VRTX",
      "source": "CNBC",
      "summary": "The stock market was little changed this morning after the S&P 500 hit records highs Tuesday.",
      "url": "https://finnhub.io/api/news?id=a57b975de029806c09eb01c4b7ec39385868263fc9dfb7e3d6ee1aa602c63b5b"
    }
  },
  {
    "ts": null,
    "headline": "Vertex’s Upgraded IgA Nephropathy Outlook Might Change The Case For Investing In Vertex (VRTX)",
    "summary": "In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing confidence in its investigational IgA nephropathy therapy and the planned use of a priority review voucher to accelerate regulatory timelines. This reassessment highlights how expectations around Vertex’s kidney pipeline and broader gene-editing portfolio are becoming increasingly central to how the business is being evaluated. We’ll now examine how this analyst upgrade,...",
    "url": "https://finnhub.io/api/news?id=6059822f75799a4d552e711bf6b80edad8993ab07f1ede566216a7ecfb0bf113",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767777280,
      "headline": "Vertex’s Upgraded IgA Nephropathy Outlook Might Change The Case For Investing In Vertex (VRTX)",
      "id": 138025920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing confidence in its investigational IgA nephropathy therapy and the planned use of a priority review voucher to accelerate regulatory timelines. This reassessment highlights how expectations around Vertex’s kidney pipeline and broader gene-editing portfolio are becoming increasingly central to how the business is being evaluated. We’ll now examine how this analyst upgrade,...",
      "url": "https://finnhub.io/api/news?id=6059822f75799a4d552e711bf6b80edad8993ab07f1ede566216a7ecfb0bf113"
    }
  }
]